Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diyushengbai tablets for azathioprine-induced leukopenia in inflammatory bowel disease
ChiCTR2300078903Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2023
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of diyu shengbai and azathioprine in leukopenia (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: white blood cell count at week 4, clinical effective rate and 3 more. Started Dec 2023; status: recruiting.
02
Drugs
diyu shengbaiazathioprine
03
Conditions
leukopenia
Beyond the preview
Go deeper on ChiCTR2300078903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078903.